Xtreem Pulse, LLC appears in FDA 510(k) records as the applicant for the PureLift Pro Max, cleared as substantially equivalent on September 11, 2026 under K262861. The filing lists the device as a transcutaneous electrical stimulator for aesthetic purposes, Class II, product code NFO, regulation number 882.5890, with the Neurology advisory committee and a Special review type. Earlier clearances in the same product line, PureLift Pro Plus (K221443) and PureLift Pro Edition (K230506), were reviewed under the same regulation and product code. The company's own published pages describe a New York base, design work in the USA and manufacturing in Japan. [1][2][5][6][3]
The 2026 PureLift Pro Max clearance
FDA records show K262861 for PureLift Pro Max, received August 13, 2026 and decided September 11, 2026 as Substantially Equivalent (SESE). The record names Xtreem Pulse, LLC as applicant, product code NFO, device class 2, regulation 882.5890, advisory committee Neurology, clearance type Special, and a summary statement. The filing was not reviewed by a third party and no Predetermined Change Control Plan was authorized. [1][2]
Earlier PureLift filings in the same product code
A June 21, 2023 FDA letter for K230506 addresses Xtreem Pulse and names PureLift Pro Edition under 21 CFR 882.5890, Class II, product code NFO, with Jacqueline Schmainda listed as regulatory consultant. An October 21, 2022 letter for K221443 names PureLift Pro Plus, submitted by Xtreem Pulse LLC with Andrew Barile as CEO and Jacqueline Schmainda as regulatory consultant; that summary identifies PureLift (K190269) as primary predicate and the Rejuvenique Model RJV-10 as reference device. [5][6]
Company description as published by the manufacturer
PureLiftLab's about page describes a fifteen-year partnership between Japanese manufacturing and U.S. design, with headquarters in New York and offices in France, Germany and Japan. It states that products are designed in the USA and manufactured in Japan in an ISO13485 facility, and that Xtreem Pulse LLC is an FDA Registered Manufacturer. Xtreem Pulse's own site describes a vertically integrated healthcare technology company, made in Japan and designed in NYC, citing 39+ years of R&D in EMS technologies, 50+ global partnerships and 4 international locations. These are company statements, not independently verified findings. [3][4]
What the filing record does and does not establish
The linked collection for this profile contains one 510(k) record, K262861, decided SESE; that count reflects the retrieved filings as of November 20, 2026 and is not a measure of total portfolio, sales or safety performance. The numbered sources do not document recalls, clinical outcome data, customer lists or commercial availability. FDA filing addresses, such as the New York addresses in the 2022 and 2023 letters, are correspondence addresses and are not treated here as headquarters. [1][5][6]

